Back to today’s briefing

Story perspectives

Revolutionary Blood Test Transforms Multiple Myeloma Diagnosis

8/9/2025

28 5

Summary

Story summary

Researchers at Dana-Farber Cancer Institute have unveiled SWIFT-seq, a groundbreaking blood test that transforms the diagnosis and monitoring of multiple myeloma. By employing single-cell sequencing to analyze circulating tumor cells, this innovative test provides a painless alternative to invasive bone marrow biopsies, enhancing risk assessment and pinpointing crucial genetic alterations that could lead to better patient outcomes.

1 of 1

Story summary

Researchers at Dana-Farber Cancer Institute have unveiled SWIFT-seq, a groundbreaking blood test that transforms the diagnosis and monitoring of multiple myeloma. By employing single-cell sequencing to analyze circulating tumor cells, this innovative test provides a painless alternative to invasive bone marrow biopsies, enhancing risk assessment and pinpointing crucial genetic alterations that could lead to better patient outcomes.